From clinical trial to prescription

Archives of General Psychiatry

Volumn 59, Issue 3, 2002, Pages 282-285

  Carpenter Jr , William T ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

CLINICAL RESEARCH; DATA ANALYSIS; DRUG INDUSTRY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; REVIEW;

EID: 0036192644     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.59.3.282     Document Type: Review

References (25)

1. Is academic medicine for sale?
2. Conflict of interest: NEJM admits breaking its own tough rules
3. Med school to relax rules on business links?
4. Policies on faculty conflicts of interest at US universities
5. Assessing faculty financial relationships with industry: A case study
6. Conflicts of interest in biomedical research
7. Conflict of interest and the public trust
8. The publication of sponsored symposiums in medical journals
9. HHS conference on conflict of interest in clinical research will raise a new question: Should research universities worry about their own conflicts of interest?
10. The kept university
11. Medical professionalism: Focusing on the real issues
12. Academia and industry: Increasingly uneasy bedfellows
13. Physicians' behavior and their interactions with drug companies
14. What's black and white and sell medicine?
15. Conference call
16. Withholding research results in academic life science
17. Separating continuing medical education from pharmaceutical marketing
18. Schizophrenia: Initial results from the schizophrenia patient outcomes research team (PORT) client survey
19. Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey
20. The effects of olanzapine on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American and International trials
21. Clinical profile of an atypical antipsychotic: Risperidone
22. Uneasy alliance: Clinical investigators and the pharmaceutical industry
23. Atypical antipsychotics in the treatment of schizophrenia -systematic overview and meta- regression analysis
24. Recent studies on the neurocognitive effects of second generation antipsychotic medications
25. Industry phase IV trials are of little or no value